Skip to main content
SpringerLink
Log in

Pathophysiology and Clinical Implications of Vascular Endothelial Growth Factor

  • Chapter
Book cover Tumor Angiogenesis

  • 1842 Accesses

Abstract

Inhibiting angiogenesis is a promising strategy to treat cancer and several other disorders, including intraocular neovascular syndromes. It is now well established that vascular endothelial growth factor (VEGF)-A is a major regulator of normal and pathological angiogenesis. VEGFA is part of a gene family that also includes P1GF, VEGF-B, VEGF-C and VEGF-D. Targeting VEGF-A resulted in a therapeutic benefit in a variety of models of cancer and intraocular neovascular syndromes. VEGF inhibitors have been recently approved by the U.S. Food and Drug Administration for the treatment of cancer and the neovascular form of age-related macular degeneration. This chapter summarizes the basic biology of VEGF-A and illustrates the clinical progress in targeting this molecule.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Achen MG, Jeltsch M, Kukk E, Makinen T, Vitali A, Wilks AF, Alitalo K, Stacker SA (1998) Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine ki-nases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci USA 95:548–553

    PubMed  CAS  Google Scholar 

  • Adamis AP, Shima DT, Tolentino MJ, Gragoudas ES, Ferrara N, Folkman J, D’Amore PA, Miller JW (1996) Inhibition of vascular endothelial growth factor prevents retinal isch-emia-associated iris neovascularization in a nonhuman primate. Arch-Ophthalmol 114:66–71

    PubMed  CAS  Google Scholar 

  • Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE, Nguyen H, Aiello LM, Ferrara N, King GL (1994) Vascu-lar endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders (see comments). N Engl J Med 331:1480–1487

    PubMed  CAS  Google Scholar 

  • Aiello LP, Pierce EA, Foley ED, Takagi H, Chen H, Riddle L, Ferrara N, King GL, Smith LE (1995) Suppression of retinal neovascularization in vivo by inhibition of vas-cular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 92:10457-10461 issn: 10027–18424

    Google Scholar 

  • Alon T, Hemo I, Itin A, Pe’er J, Stone J, Keshet E (1995) Vas-cular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1:1024–1028 issn: 1078–8956

    PubMed  CAS  Google Scholar 

  • Asahara T, Murohara T, Sullivan A, Silver M, van derZee R, Li T, Witzenbichler B, Schatteman G, Isner JM (1997) Isolation of putative progenitor endothelial cells for an-giogenesis. Science 275:964–967

    PubMed  CAS  Google Scholar 

  • Asano M, Yukita A, Matsumoto T, Kondo S, Suzuki H (1995) Inhibition of tumor growth and metastasis by an immu-noneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability fac-torl21. Cancer Res 55:5296–5301

    PubMed  CAS  Google Scholar 

  • Bagri A, Tessier-Lavigne M (2002) Neuropilins as Semapho-rin receptors: in vivo functions in neuronal cell migra-tion and axon guidance. Adv Exp Med Biol 515:13–31

    PubMed  CAS  Google Scholar 

  • Barbazetto I, Burdan A, Bressler NM, Bressler SB, Haynes L, Kapetanios AD, Lukas J, Olsen K, Potter M, Reaves A, Rosenfeld P, Schachat AP, Strong HA, Wenkenstern A (2003) Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angio-graphie guidelines for evaluation and treatment-TAP and VIP report No. 2. Arch Ophthalmol 121:1253–1268

    CAS  Google Scholar 

  • Barleon B, Totzke F, Herzog C, Blanke S, Kremmer E, Siemeis-ter G, Marme D, Martiny-Baron G (1997) Mapping of the sites for ligand binding and receptor dimerization at the extracellular domain of the vascular endothelial growth factor receptor FLT-1. J Biol Chem 272:10382–10388

    CAS  Google Scholar 

  • Bassett DL (1943) The changes in the vascular pattern of the ovary of the albino rat during the estrous cycle. Am J Anat 73:251–278

    Google Scholar 

  • Bates DO, Cui TG, Doughty JM, Winkler M, Sugiono M, Shields JD, Peat D, Gillatt D, Harper SJ (2002) VEGF(165)b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res 62:4123–4131

    PubMed  CAS  Google Scholar 

  • Ben-Av P, Crofford LJ, Wilder RL, Hla T (1995) Induction of vascular endothelial growth factor expression in synovial fibroblasts. FEBS Lett 372:83–87

    PubMed  CAS  Google Scholar 

  • Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E (1999) Se-lective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal (see comments). J Clin Invest 103:159–165

    PubMed  CAS  Google Scholar 

  • Berkman RA, Merrill MJ, Reinhold WC, Monacci WT, Sax-ena A, Clark WC, Robertson JT, Ali IU, Oldfield EH (1993) Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms. J Clin Invest 91:153–159

    PubMed  CAS  Google Scholar 

  • Borgstrom P, Hillan KJ, Sriramarao P, Ferrara N (1996) Com-plete inhibition of angiogenesis and growth of microtu-mors by anti-vascular endothelial growth factor neutral-izing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res 56:4032–4039

    PubMed  CAS  Google Scholar 

  • Borgstrom P, Bourdon MA, Hillan KJ, Sriramarao P, Ferrara N (1998) Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo. Prostate 35:1–10

    PubMed  CAS  Google Scholar 

  • Borgstrom P, Gold DP, Hillan KJ, Ferrara N (1999) Impor-tance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Res 19:4203–4214

    PubMed  CAS  Google Scholar 

  • Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Dvorak HF, Senger DR (1993) Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol 143:1255–1262 issn: 0002–9440

    PubMed  CAS  Google Scholar 

  • Brown LF, Berse B, Jackman RW, Tognazzi K, Guidi AJ, Dvorak HF, Senger DR, Connolly JL, Schnitt SJ (1995) Ex-pression of vascular permeability factor (vascular endo-thelial growth factor) and its receptors in breast cancer. Hum Pathol 26:86–91 issn: 0046–8177

    PubMed  CAS  Google Scholar 

  • Broxmeyer HE, Cooper S, Li ZH, Lu L, Song HY, Kwon BS, Warren RE, Donner DB (1995) Myeloid progenitor cell regulatory effects of vascular endothelial cell growth fac-tor. Int J Hematol 62:203–215 issn: 0925–5710

    PubMed  CAS  Google Scholar 

  • Carlevaro MF, Cermelli S, Cancedda R, Descalzi Cancedda F (2000) Vascular endothelial growth factor (VEGF) in cartilage neovascularization and chondrocyte differen-tiation: auto-paracrine role during endochondral bone formation. J Cell Sci 113:59–69

    PubMed  CAS  Google Scholar 

  • Carmeliet P (2003) Angiogenesis in health and disease. Nat Med 9:653–660

    PubMed  CAS  Google Scholar 

  • Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoeck A, Harpal K, Eberhardt C, Declercq C, Pawling J, Moons L, Collen D, Risau W, Nagy A (1996) Abnormal blood vessel develop-ment and lethality in embryos lacking a single VEGF al-lele. Nature 380:435–439 issn: 0028-0836

    PubMed  CAS  Google Scholar 

  • Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, de Mol M, Wu Y, Bono F, Devy L, Beck H, Scholz D, Acker T, DiPalma T, Dewerchin M, Noel A, Stalmans I, Barra A, Blacher S, Vandendriessche T, Ponten A, Eriks-son U, Plate KH, Foidart JM, Schaper W, Charnock-Jones DS, Hicklin DJ, Herbert JM, Collen D, Persico MG (2001) Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med, 7:575–583

    PubMed  CAS  Google Scholar 

  • Chen Y, Wiesmann C, Fuh G, Li B, Christinger HW, McKay P, deVos AM, Lowman HB (1999) Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J Mol Biol 293:865–881

    PubMed  CAS  Google Scholar 

  • Christenson LK, Stouffer RL (1997) Follicle-stimulating hor-mone and luteinizing hormone/chorionic gonadotropin stimulation of vascular endothelial growth factor produc-tion by macaque granulosa cells from pre-and periovula-tory follicles. J Clin Endocrinol Metab 82:2135–2142

    PubMed  CAS  Google Scholar 

  • Clauss M, Gerlach M, Gerlach H, Brett J, Wang F, Familletti PC, Pan YC, Olander JV, Connolly DT, Stern D (1990) Vas-cular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 172:1535–1545

    PubMed  CAS  Google Scholar 

  • Cohen T, Nahari D, Cerem LW, Neufeld G, Levi BZ (1996) In-terleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem 271:736–741 issn: 0021-9258

    PubMed  CAS  Google Scholar 

  • Congdon N, O ’Colmain B, Klaver CC, Klein R, Munoz B, Friedman DS, Kempen J, Taylor HR, Mitchell P (2004) Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 122:477–485

    PubMed  Google Scholar 

  • Connolly DT, Olander JV, Heuvelman D, Nelson R, Monsell R, Siegel N, Haymore BL, Leimgruber R, Feder J (1989) Human vascular permeability factor. Isolation from U937 cells. J Biol Chem 264:20017–20024

    PubMed  CAS  Google Scholar 

  • Davis-Smyth T, Chen H, Park J, Presta LG, Ferrara N (1996) The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade. EMBO J 15:4919–4927

    PubMed  CAS  Google Scholar 

  • Davis-Smyth T, Presta LG, Ferrara N (1998) Mapping the charged residues in the second immunoglobulin-like do-main of the vascular endothelial growth factor/placenta growth factor receptor Flt-1 required for binding and structural stability. J Biol Chem 273:3216–3222

    PubMed  CAS  Google Scholar 

  • DePalma M, Venneri MA, Roca C, Naldini L (2003) Target-ing exogenous genes to tumor angiogenesis by transplan-tation of genetically modified hematopoietic stem cells. Nat Med 9:789–795

    PubMed  Google Scholar 

  • DePalma M, Venneri MA, Galli R, Sergi LS, Politi LS, Sam-paolesi M, Naldini L (2005) Tie2 identifies a hematopoi-etic lineage of proangiogenic monocytes required for tu-mor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 8:211–226

    PubMed  Google Scholar 

  • DeVries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Wil-liams LT (1992) The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255:989–991

    PubMed  Google Scholar 

  • Dong J, Grunstein J, Tejada M, Peale F, Frantz G, Liang WC, Bai W, Yu L, Kowalski J, Liang X, Fuh G, Ferber HP, Ferrara N (2004) VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis. EMBO J 23:2800–2810

    PubMed  CAS  Google Scholar 

  • Ellis LM (2005) Bevacizumab. Nat Rev Drug Discov [Suppl] S8–S9

    Google Scholar 

  • Ellis LM, Takahashi Y, Fenoglio CJ, Cleary KR, Bucana CD, Evans DB (1998) Vessel counts and vascular endothelial growth factor expression in pancreatic adenocarcinoma. Eur J Cancer 34:337–340

    PubMed  CAS  Google Scholar 

  • Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Ferrara N, Gerber HP, Kikkawa Y, Miner JH, Quaggin SE (2003) Glo-merular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 111:707–716

    PubMed  CAS  Google Scholar 

  • Ferrara N (2002) VEGF and the quest for tumour angiogen-esis factors. Nat Rev Cancer 2:795–803

    PubMed  CAS  Google Scholar 

  • Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25:581–611

    PubMed  CAS  Google Scholar 

  • Ferrara N, Davis-Smyth T (1997) The biology of vascular en-dothelial growth factor. Endocr Rev 18:4–25

    PubMed  CAS  Google Scholar 

  • Ferrara N, Henzel WJ (1989) Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vas-cular endothelial cells. Biochem Biophys Res Commun 161:851–858

    PubMed  CAS  Google Scholar 

  • Ferrara N, Kerbel RS (2005) Angiogenesis as a therapeutic target. Nature 438:967–974

    PubMed  CAS  Google Scholar 

  • Ferrara N, Houck K, Jakeman L, Leung DW (1992) Molecu-lar and biological properties of the vascular endothelial growth facmily of proteins. Endocr Rev 18:32

    Google Scholar 

  • Ferrara N, CarverMoore K, Chen H, Dowd M, Lu L, O’Shea KS, Powell Braxton L, Hillan KJ, Moore MW (1996) Het-erozygous embryonic lethality induced by targeted in-activation of the VEGF gene. Nature 380:439–442 issn: 0028–0836

    PubMed  CAS  Google Scholar 

  • Ferrara N, Chen H, Davis-Smyth T, Gerber H-P, Nguyen T-N, Peers D, Chisholm V, Hillan KJ, Schwall RH (1998) Vas-cular endothelial growth factor is essential for corpus luteum angiogenesis. Nat Med 4:336–340

    PubMed  CAS  Google Scholar 

  • Ferrara N, Damico LA, Shams N, Lowman H, Kim R (2006) Developmemt of Ranibizumab, an anti-VEGF Fab for the therapy of neovascular age-related macular degenera-tion. Retina 26:859–870

    PubMed  Google Scholar 

  • Ferris FL 3rd, Fine SL, Hyman L (1984) Age-related macular degeneration and blindness due to neovascular macu-lopathy. Arch Ophthalmol 102:1640–1642

    PubMed  Google Scholar 

  • Folkman J (1971) Tumor angiogenesis: therapeutic implica-tions. N Engl J Med 285:1182–1186

    PubMed  CAS  Google Scholar 

  • Folkman J (1995) Angiogenesis in cancer, vascular, rheuma-toid and other disease. Nat Med 1:27–31 issn: 1078-8956

    PubMed  CAS  Google Scholar 

  • Fong GH, Rossant J, Gertsenstein M, Breitman ML (1995) Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376:66–70

    PubMed  CAS  Google Scholar 

  • Fong GH, Zhang L, Bryce DM, Peng J (1999) Increased he-mangioblast commitment, not vascular disorganization, is the primary defect in flt-1 knock-out mice. Develop-ment 126:3015–3025

    CAS  Google Scholar 

  • Frank S, Hubner G, Breier G, Longaker MT, Greenhalg DG, Werner S (1995) Regulation of VEGF expression in cultured keratinocytes. Implications for normal and impaited wound healing. J Biol Chem 270:12607–12613

    PubMed  CAS  Google Scholar 

  • Fraser HM, Dickson SE, Lunn SF, Wulff C, Morris KD, Car-roll VA, Bicknell R (2000) Suppression of luteal angio-genesis in the primate after neutralization of vascular endothelial growth factor. Endocrinology 141:995–1000

    PubMed  CAS  Google Scholar 

  • Fujio Y, Walsh K (1999) Akt mediates cytoprotection of en-dothelial cells by vascular endothelial growth factor in an anchorage-dependent manner. J Biol Chem 274:16349–16354

    PubMed  CAS  Google Scholar 

  • Gasparini G, Longo R, Toi M, Ferrara N (2005) Angiogenic inhibitors: a new therapeutic strategy in oncology. Nat Clin Pract Oncol 2:562–577

    PubMed  CAS  Google Scholar 

  • Gerber HP, Ferrara N (2005) Pharmacology and pharmaco-dynamics of bevacizumab as monotherapy or in com-bination with cytotoxic therapy in preclinical studies. Cancer Res 65:671–680

    PubMed  CAS  Google Scholar 

  • Gerber HP, Condorelli F, Park J, Ferrara N (1997) Differen-tial transcriptional regulation of the two VEGF receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hy-poxia. J Biol Chem 272:23659–23667

    PubMed  CAS  Google Scholar 

  • Gerber HP, Dixit V, Ferrara N (1998a) Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem 273:13313–13316

    PubMed  CAS  Google Scholar 

  • Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V, Ferrara N (1998b) VEGF regulates endothelial cell survival by the PI3-kinase/Akt signal transduction path-way. Requirement for Flk-1/KDR activation. J Biol Chem 273:30336–30343

    PubMed  CAS  Google Scholar 

  • Gerber HP, Hillan KJ, Ryan AM, Kowalski J, Keller G-A, Rangell L, Wright BD, Radtke F, Aguet M, Ferrara N (1999a) VEGF is required for growth and survival in neo-natal mice. Development 126:1149–1159

    PubMed  CAS  Google Scholar 

  • Gerber HP, Vu TH, Ryan AM, Kowalski J, Werb Z, Ferrara N (1999b) VEGF couples hypertrophic cartilage remodel-ing, ossification and angiogenesis during endochondral bone formation. Nat Med 5:623–628

    PubMed  CAS  Google Scholar 

  • Gerber HP, Kowalski J, Sherman D, Eberhard DA, Ferrara N (2000) Complete inhibition of rhabdomyosarcoma xeno-graft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth fac-tor. Cancer Res 60:6253–6258

    PubMed  CAS  Google Scholar 

  • Gerber H-P, Malik A, Solar GP, Sherman D, Liang X-H, Meng G, Hong K, Marsters J, Ferrara N (2002) Vascular endo-thelial growth factor regulates hematopoietic stem cell survival by an internal autocrine loop mechanism. Na-ture 417:954–958

    CAS  Google Scholar 

  • Gille H, Kowalski J, Yu L, Chen H, Pisabarro MT, Davis-Smyth T, Ferrara N (2000) A repressor sequence in the juxtamembrane domain of Flt-1 (VEGFR-1) constitu-tively inhibits VEGF-dependent PI 3 kinase activation and endothelial cell migration. EMBO J 19:4064–4073

    PubMed  CAS  Google Scholar 

  • Gille H, Kowalski J, Li B, LeCouter J, Moffat B, Zioncheck T, Pelletier N, Ferrara N (2001) Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific VEGF mutants. J Biol Chem 276:3222–3230

    PubMed  CAS  Google Scholar 

  • Goede V, Schmidt T, Kimmina S, Kozian D, Augustin HG (1998) Analysis of blood vessel maturation processes dur-ing cyclic ovarian angiogenesis. Lab Invest 78:1385–1394

    PubMed  CAS  Google Scholar 

  • Goldman CK, Kendall RL, Cabrera G, Soroceanu L, Heike Y, Gillespie GY, Siegal GP, Mao X, Bett AJ, Huckle WR, Thomas KA, Curiel DT (1998) Paracrine expression of a native soluble vascular endothelial growth factor recep-tor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci USA 95:8795–8800

    PubMed  CAS  Google Scholar 

  • Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR (2004) Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351:2805–2816

    PubMed  CAS  Google Scholar 

  • Grugel S, Finkenzeller G, Weindel K, Barleon B, Marme D (1995) Both v-Ha-Ras and v-Raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells. J Biol Chem 270:25915–25919 issn: 20021-29258

    PubMed  CAS  Google Scholar 

  • Guerrin M, Moukadiri H, Chollet P, Moro F, Dutt K, Male-caze F, Plouet J (1995) Vasculotropin/vascular endothelial growth factor is an autocrine growth factor for human retinal pigment epithelial cells cultured in vitro. J Cell Physiol 164:385–394

    PubMed  CAS  Google Scholar 

  • Guidi AJ, Abu Jawdeh G, Tognazzi K, Dvorak HF, Brown LF (1996) Expression of vascular permeability factor (vascu-lar endothelial growth factor) and its receptors in endo-metrial carcinoma. Cancer 78:454–460 issn: 0008-0543x

    PubMed  CAS  Google Scholar 

  • Hattori K, Dias S, Heissig B, Hackett NR, Lyden D, Tateno M, Hicklin DJ, Zhu Z, Witte L, Crystal RG, Moore MA, Rafii S (2001) Vascular endothelial growth factor and angiopoi-etin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J Exp Med 193:1005–1014

    PubMed  CAS  Google Scholar 

  • Hattori K, Heissig B, Wu Y, Dias S, Tejada R, Ferris B, Hicklin DJ, Zhu Z, Bohlen P, Witte L, Hendrikx J, Hackett NR, Crystal RG, Moore MA, Werb Z, Lyden D, Rafii S (2002) Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow mi-croenvironment. Nat Med 8:841–849

    PubMed  CAS  Google Scholar 

  • Hiratsuka S, Nakamura K, Iwai S, Murakami M, Itoh T, Ki-jima H, Shipley JM, Senior RM, Shibuya M (2002) MMP9 induction by vascular endothelial growth factor recep-tor-1 is involved in lung-specific metastasis. Cancer Cell 2:289–300

    PubMed  CAS  Google Scholar 

  • Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, Ioffe E, Huang T, Radziejewski C, Bailey K, Fandl JP, Daly T, Wiegand SJ, Yancopoulos GD, Rudge JS (2002) VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 99:11393–11398

    PubMed  CAS  Google Scholar 

  • Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung DW (1991) The vascular endothelial growth factor family: identification of a fourth molecular species and charac-terization of alternative splicing of RNA. Mol Endocrinol 5:1806–1814

    PubMed  CAS  Google Scholar 

  • Houck KA, Leung DW, Rowland AM, Winer J, Ferrara N (1992) Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mecha-nisms. J Biol Chem 267:26031–26037

    PubMed  CAS  Google Scholar 

  • Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hain-sworth H, Helm W, Berlin J, Baron A, Griffing S, Hol-mgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342

    PubMed  CAS  Google Scholar 

  • Iliopoulos O, Levy AP, Jiang C, Kaelin WG Jr, Goldberg MA (1996) Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci USA 93:10595–10599

    PubMed  CAS  Google Scholar 

  • Inoue M, Hager JH, Ferrara N, Gerber HP, Hanahan D (2002) VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell 1:193–202

    PubMed  CAS  Google Scholar 

  • Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, Salic A, Asara JM, Lane WS, Kaelin WG Jr (2001) HIF-alpha tar-geted for VHL-mediated destruction by proline hydroxyl-ation: implications for 02 sensing. Science 292:464–468

    PubMed  CAS  Google Scholar 

  • Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ, Maxwell PH, Pugh CW, Ratcliffe PJ (2001) Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292:468–472

    PubMed  CAS  Google Scholar 

  • Jain RK (2003) Molecular regulation of vessel maturation. Nat Med 9:685–693

    PubMed  CAS  Google Scholar 

  • Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58–62

    PubMed  CAS  Google Scholar 

  • Jain RK, Duda DG, Clark JW, Loeffler JS (2006) Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 3:24–40

    PubMed  CAS  Google Scholar 

  • Jakeman LB, Winer J, Bennett GL, Altar CA, Ferrara N (1992) Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues. J Clin Invest 89:244–253

    PubMed  CAS  Google Scholar 

  • Jakeman LB, Armanini M, Philips HS, Ferrara N (1993) De-velopmental expression of binding sites and mRNA for vascular endothelial growth factor suggests a role for this protein in vasculogenesis and angiogenesis. Endocrinol-ogy 133:848–859

    CAS  Google Scholar 

  • Jingjing L, Xue Y, Agarwal N, Roque RS (1999) Human Müller cells express VEGF183, a novel spliced variant of vascular endothelial growth factor. Invest Ophthalmol Vis Sci 40:752–759

    PubMed  CAS  Google Scholar 

  • Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Ne-munaitis JJ, Jablons DM, Langer CJ, DeVore RF 3rd, Gaud-reault J, Damico LA, Holmgren E, Kabbinavar F (2004) Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and pa-clitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22:2184–2191

    PubMed  CAS  Google Scholar 

  • Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, Saksela O, Kalkkinen N, Alitalo K (1996) A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor ty-rosine kinases. EMBO J 15:1751 issn: 0261-4189

    PubMed  CAS  Google Scholar 

  • Karkkainen MJ, Makinen T, Alitalo K (2002) Lymphatic en-do thelium: a new frontier of metastasis research. Nat Cell Biol 4:E2–E5

    PubMed  CAS  Google Scholar 

  • Karkkainen MJ, Haiko P, Sainio K, Partanen J, Taipale J, Petrova TV, Jeltsch M, Jackson DG, Talikka M, Rauvala H, Betsholtz C, Alitalo K (2004) Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol 5:74–80

    PubMed  CAS  Google Scholar 

  • Kawasaki T, Kitsukawa T, Bekku Y, Matsuda Y, Sanbo M, Yagi T, Fujisawa H (1999) A requirement for neuropilin-1 in embryonic vessel formation. Development 126:4895–4902

    PubMed  CAS  Google Scholar 

  • Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J, Connolly DT (1989) Vascular permeability factor, an en-dothelial cell mitogen related to PDGF. Science 246:1309–1312

    PubMed  CAS  Google Scholar 

  • Kendall RL, Thomas KA (1993) Inhibition of vascular endo-thelial cell growth factor activity by an endogenously en-coded soluble receptor. Proc Natl Acad Sci USA 90:10705–10709

    PubMed  CAS  Google Scholar 

  • Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 362:841–844

    PubMed  CAS  Google Scholar 

  • Kishimoto J, Ehama R, Ge Y, Kobayashi T, Nishiyama T, Det-mar M, Burgeson RE (2000) In vivo detection of human vascular endothelial growth factor promoter activity in transgenic mouse skin. Am J Pathol 157:103–110

    PubMed  CAS  Google Scholar 

  • Klagsbrun M, D’Amore PA (1991) Regulators of angiogenesis. Annu Rev Physiol 53:217–239

    PubMed  CAS  Google Scholar 

  • Klagsbrun M, Eichmann A (2005) A role for axon guid-ance receptors and ligands in blood vessel development and tumor angiogenesis. Cytokine Growth Factor Rev 16:535–548

    PubMed  CAS  Google Scholar 

  • Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P, Kerbel RS (2000) Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity (see comments). J Clin Invest 105:R15–R24

    PubMed  CAS  Google Scholar 

  • Kozin SV, Boucher Y, Hicklin DJ, Bohlen P, Jain RK, Suit HD (2001) Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res 61:39–44

    PubMed  CAS  Google Scholar 

  • Kuo CJ, Farnebo F, Yu EY, Christofferson R, Swearigen RA, Carter R, von Recum HA, Yuan J, Kumihara J, Flynn E, D’Amato R, Folkman J, Mulligan RC (2001) Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc Natl Acad Sci USA 98:4605–4610

    PubMed  CAS  Google Scholar 

  • Lange T, Guttmann-Raviv N, Baruch L, Machluf M, Neufeld G (2003) VEGF162, a new heparin-binding vascular en-dothelial growth factor splice form that is expressed in transformed human cells. J Biol Chem 278:17164–17169

    PubMed  CAS  Google Scholar 

  • LeCouter J, Moritz DR, Li B, Phillips GL, Liang XH, Gerber HP, Hillan KJ, Ferrara N (2003) Angiogenesis-indepen-dent endothelial protection of liver: role of VEGFR-1. Sci-ence 299:890–893

    CAS  Google Scholar 

  • Lee CG, Heijn M, di Tomaso E, Griffon-Etienne G, Ancukie-wicz M, Koike C, Park KR, Ferrara N, Jain RK, Suit HD, Boucher Y (2000) Anti-vascular endothelial growth factor treatment augments tumor radiation response under nor-moxic or hypoxic conditions. Cancer Res 60:5565–5570

    PubMed  CAS  Google Scholar 

  • Lee J, Gray A, Yuan J, Luoh SM, Avraham H, Wood WI (1996) Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase re-ceptor Flt4. Proc Natl Acad Sci USA 93:1988–1992 issn: 0027-8424

    PubMed  CAS  Google Scholar 

  • Lee S, Jilani SM, Nikolova GV, Carpizo D, Iruela-Arispe ML (2005) Processing of VEGF-A by matrix metalloprotein-ases regulates bioavailability and vascular patterning in tumors. J Cell Biol 169:681–691

    PubMed  CAS  Google Scholar 

  • Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N (1989) Vascular endothelial growth factor is a secreted angiogenic mitogen. Science, 246:1306–1309

    PubMed  CAS  Google Scholar 

  • Lonser RR, Glenn GM, Walther M, Chew EY, Libutti SK, Linehan WM, Oldfield EH (2003) Von Hippel-Lindau disease. Lancet 361:2059–2067

    PubMed  CAS  Google Scholar 

  • Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, Chadburn A, Heissig B, Marks W, Witte L, Wu Y, Hicklin D, Zhu Z, Hackett NR, Crystal RG, Moore MA, Hajjar KA, Manova K, Benezra R, Rafii S (2001) Impaired recruit-ment of bone-marrow-derived endothelial and hemato-poietic precursor cells blocks tumor angiogenesis and growth. Nat Med 7:1194–1201

    PubMed  CAS  Google Scholar 

  • Lyttle DJ, Fraser KM, Flemings SB, Mercer AA, Robinson AJ (1994) Homologs of vascular endothelial growth factor are encoded by the poxvirus orf virus. J Virol 68:84–92

    PubMed  CAS  Google Scholar 

  • Maglione D, Guerriero V, Viglietto G, Delli-Bovi P, Persico MG (1991) Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci USA 88:9267–9271

    PubMed  CAS  Google Scholar 

  • Maglione D, Guerriero V, Viglietto G, Ferraro MG, Apre-likova O, Alitalo K, del Vecchio S, Lei KJ, Chou JY, Per-sico MG (1993) Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (P1GF), are transcribed from a single gene of chromosome 14. On-cogene 8:925–931

    CAS  Google Scholar 

  • Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegend SJ, Radziejewski C, Compton D, McClain J, Aldrich TH, Papadopulos N, Daly TJ, Davis S, Sato TN, Yancopoulos GD (1997) Angiopoietin-2, a natural antagonist for Tie-2 that disrupts in vivo angiogenesis. Science 277:55–60

    PubMed  CAS  Google Scholar 

  • Malecaze F, Clemens S, Simorer-Pinotel V, Mathis A, Chollet P, Favard P, Bayard F, Plouet J (1994) Detection of vascular endothelial growth factor mRNA and vascular endothe-lial growth factor-like activity in proliferative diabetic retinopathy. Arch Ophthalmol 112:1476–1482

    PubMed  CAS  Google Scholar 

  • Matsumoto T, Claesson-Welsh L (2001) VEGF receptor signal transduction. Science’s STKE 112 (RE21):1–17

    Google Scholar 

  • Maxwell PH, Ratcliffe PJ (2002) Oxygen sensors and angio-genesis. Semin Cell Dev Biol 13:29–37

    PubMed  CAS  Google Scholar 

  • Melnyk O, Shuman MA, Kim KJ (1996) Vascular endothelial growth factor promotes tumor dissemination by a mech-anism distinct from its effect on primary tumor growth. Cancer-Res, 56:921–924 issn: 0008-5472

    PubMed  CAS  Google Scholar 

  • Mesiano S, Ferrara N, Jaffe RB (1998) Role of vascular en-dothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol 153:1249–1256

    PubMed  CAS  Google Scholar 

  • Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatra-man AS (2005) Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 112:1035–1047

    PubMed  Google Scholar 

  • Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A (1994) Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367:576–579 issn: 0028-0836

    PubMed  CAS  Google Scholar 

  • Millauer B, Wizigmann Voos S, Schnurch H, Martinez R, Möller NP, Risau W, Ullrich A (1993) High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell, 72:835–846 issn: 0092-8674

    PubMed  CAS  Google Scholar 

  • Miller JW, Adamis AP, Shima DT, D’Amore PA, Moulton RS, O’Reilly MS, Folkman J, Dvorak HF, Brown LF, Berse B, Yeo TK, Yeo KT (1994) Vascular endothelial growth fac-tor/vascular permeability factor is temporally and spa-tially correlated with ocular angiogenesis in a primate model. Am J Pathol 145:574–584 issn: 0002-9440

    PubMed  CAS  Google Scholar 

  • Mole DR, Maxwell PH, Pugh CW, Ratcliffe PJ (2001) Regula-tion of HIF by the von Hippel-Lindau tumour suppres-sor: implications for cellular oxygen sensing. IUBMB Life 52:43–47

    PubMed  CAS  Google Scholar 

  • Morgan B, Thomas AL, Drevs J, Hennig J, Buchert M, Jivan A, Horsfield MA, Mross K, Ball HA, Lee L, Mietlowski W, Fuxuis S, Unger C, O’Byrne K, Henry A, Cherryman GR, Laurent D, Dugan M, Marme D, Steward WP (2003) Dynamic contrast-enhanced magnetic resonance imag-ing as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothe-lial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 21:3955–3964

    PubMed  CAS  Google Scholar 

  • Motzer RJ, Dror Michaelson M, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, Deprimo SE, Li JZ, Bello CL, Theuer CP, George DJ, Rini BI (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and plate-let-derived growth factor receptor, in patients with meta-static renal cell carcinoma. J Clin Oncol 24:16–24

    PubMed  CAS  Google Scholar 

  • Neufeld G, Cohen T, Shraga N, Lange T, Kessler O, Herzog Y (2002) The neuropilins: multifunctional semaphorin and VEGF receptors that modulate axon guidance and angio-genesis. Trends Cardiovasc Med 12:13–19

    PubMed  CAS  Google Scholar 

  • Nicol D, Hii SI, Walsh M, Teh B, Thompson L, Kennett C, Gotley D (1997) Vascular endothelial growth factor expression is increased in renal cell carcinoma. J Urol 157:1482–1486

    PubMed  CAS  Google Scholar 

  • Oberg-Welsh C, Sandier S, Andersson A, Welsh M (1997) Effects of vascular endothelial growth factor on pancre-atic duct cell replication and the insulin production of fetal islet-like cell clusters in vitro. Mol Cell Endocrinol 126:125–132

    PubMed  CAS  Google Scholar 

  • Ogawa S, Oku A, Sawano A, Yamaguchi S, Yazaki Y, Shibuya M (1998) A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially uti-lizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain. J Biol Chem 273:31273–31282

    PubMed  CAS  Google Scholar 

  • Okada F, Rak JW, Croix BS, Lieubeau B, Kaya M, Roncari L, Shirasawa S, Sasazuki T, Kerbel RS (1998) Impact of onco-genes in tumor angiogenesis: mutant K-ras upregulation of vascular endothelial growth factor/vascular perme-ability factor is necessary, but not sufficient for tumori-genicity of human colorectal carcinoma cells. Proc Natl Acad Sci USA 95:3609–3614

    PubMed  CAS  Google Scholar 

  • Olofsson B, Pajusola K, Kaipainen A, von Euler G, Joukov V, Saksela O, Orpana A, Pettersson RF, Alitalo K, Eriksson U (1996) Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci USA 93:2576–2581 issn: 0027-8424

    PubMed  CAS  Google Scholar 

  • Olofsson B, Korpelainen E, Pepper MS, Mandriota SJ, Aase K, Kumar V, Gunji Y, Jeltsch MM, Shibuya M, Alitalo K, Eriksson U (1998) Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plas-minogen activator activity in endothelial cells. Proc Natl Acad Sci USA 95:11709–11714

    PubMed  CAS  Google Scholar 

  • Orlandini M, Marconcini L, Ferruzzi R, Oliviero S (1996) Identification of a c-fos-induced gene that is related to the platelet-derived growth factor/vascular endothelial growth factor family [corrected; erratum to be pub-lished]. Proc Natl Acad Sci USA 93:11675–11680

    PubMed  CAS  Google Scholar 

  • Ostendorf T, Kunter U, Eitner F, Loos A, Regele H, Kerjaschki D, Henninger DD, Janjic N, Floege J (1999) VEGF(165) mediates glomerular endothelial repair. J Clin Invest 104:913–923

    PubMed  CAS  Google Scholar 

  • Ozaki H, Seo MS, Ozaki K, Yamada H, Yamada E, Okamoto N, Hofmann F, Wood JM, Campochiaro PA (2000) Block-ade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neo-vascularization. Am J Pathol 156:697–707

    PubMed  CAS  Google Scholar 

  • Pajusola K, Aprelikova O, Korhonen J, Kaipainen A, Per-tovaara L, Alitalo R, Alitalo K (1992) FLT4 receptor ty-rosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines [published erratum appears in Cancer Res 1993, 53:3845]. Cancer Res 52:5738–5743 issn: 0008-5472

    Google Scholar 

  • Park JE, Keller G-A, Ferrara N (1993) The vascular endo-thelial growth factor isoforms (VEGF): differential de-position into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell 4:1317–1326

    PubMed  CAS  Google Scholar 

  • Park JE, Chen HH, Winer J, Houck KA, Ferrara N (1994) Pla-centa growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem 269:25646–25654 issn: 20021-29258

    PubMed  CAS  Google Scholar 

  • Pepper MS (2001) Extracellular proteolysis and angiogen-esis. Thromb Haemost 86:346–355

    PubMed  CAS  Google Scholar 

  • Pepper MS, Ferrara N, Orci L, Montesano R (1992) Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun 189:824–831

    PubMed  CAS  Google Scholar 

  • Pepper MS, Wasi S, Ferrara N, Orci L, Montesano R (1994) In vitro angiogenic and proteolytic properties of bovine lymphatic endothelial cells. Exp Cell Res 210:298–305

    PubMed  CAS  Google Scholar 

  • Pertovaara L, Kaipainen A, Mustonen T, Orpana A, Fer-rara N, Saksela O, Alitalo K (1994) Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. J Biol Chem 269:6271–6274

    PubMed  CAS  Google Scholar 

  • Phillips HS, Hains J, Leung DW, Ferrara N (1990) Vascular endothelial growth factor is expressed in rat corpus lu-teum. Endocrinology 127:965–967

    PubMed  CAS  Google Scholar 

  • Phillips HS, Armanini M, Stavrou D, Ferrara N, Westphal M (1993) Intense focal expression of vascular endothelial growth factor mRNA in human intracranial neoplasms: association with regions of necrosis. Int J Oncol 2:913–919

    CAS  Google Scholar 

  • Phtodynamic Therapy of Subfoveal Choroidal Neovascular-ization in Age-related Macular Degeneration With Verte-porfin (1999) One-year results of 2 randomized clinical trials — TAP report 1. Arch Ophthalmol 117:1329–1345

    Google Scholar 

  • Pierce EA, Foley ED, Smith LE (1996) Regulation of vascular endothelial growth factor by oxygen in a model of reti-nopathy of prematurity (see comments). Arch Ophthal-mol 114:1219–1228

    CAS  Google Scholar 

  • Plate KH, Breier G, Weich HA, Risau W (1992) Vascular en-dothelial growth factor is a potential tumour angiogene-sis factor in human gliomas in vivo. Nature 359:845–848

    PubMed  CAS  Google Scholar 

  • Plouet J, Moukadiri HJ (1990) Characerization of the recep-tors for vasculotropin on bovine adrenal cortex-derived capillary endothelial cells. J Biol Chem 265:22071–22075

    PubMed  CAS  Google Scholar 

  • Poltorak Z, Cohen T, Sivan R, Kandelis Y, Spira G, Vlodavsky I, Keshet E, Neufeld G (1997) VEGF145, a secreted vascu-lar endothelial growth factor isoform that binds to extra-cellular matrix. J Biol Chem 272:7151–7158

    PubMed  CAS  Google Scholar 

  • Poole AR (ed) (1991) Cartilage: molecular aspects. CRC Press, Boca Raton, FL, pp 179–211

    Google Scholar 

  • Presta LG, Chen H, O’Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, Ferrara N (1997) Humanization of an anti-VEGF monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57:4593–4599

    PubMed  CAS  Google Scholar 

  • Prewett M, Huber J, Li Y, Santiago A, O’Connor W, King K, Overholser J, Hooper A, Pytowski B, Witte L, Bohlen P, Hicklin DJ (1999) Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhib-its tumor angiogenesis. Cancer Res 59:5209–5218

    PubMed  CAS  Google Scholar 

  • Pugh CW, Ratcliffe PJ (2003) Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 9:677–684

    PubMed  CAS  Google Scholar 

  • Quinn TP, Peters KG, de Vries C, Ferrara N, Williams LT (1993) Fetal liver kinase 1 is a receptor for vascular en-dothelial growth factor and is selectively expressed in vascular endothelium. Proc Natl Acad Sci USA 90:7533–7537

    PubMed  CAS  Google Scholar 

  • Rafii S, Meeus S, Dias S, Hattori K, Heissig B, Shmelkov S, Rafii D, Lyden D (2002) Contribution of marrow-derived progenitors to vascular and cardiac regeneration. Semin Cell Dev Biol 13:61–67

    PubMed  CAS  Google Scholar 

  • Ravindranath N, Little-Ihrig L, Phillips HS, Ferrara N, Zeleznik AJ (1992) Vascular endothelial growth factor messenger ribonucleic acid expression in the primate ovary. Endocrinology 131:254–260

    PubMed  CAS  Google Scholar 

  • Risau W (1997) Mechanisms of angiogenesis. Nature 386:671–674

    PubMed  CAS  Google Scholar 

  • Risau W, Flamme I (1995) Vasculogenesis. Annu Rev Cell Dev Biol 11:73–91

    CAS  Google Scholar 

  • Robinson GS, Pierce EA, Rook SL, Foley E, Webb R, Smith LE (1996) Oligodeoxynucleotides inhibit retinal neovascu-larization in a murine model of proliferative retinopathy. Proc Natl Acad Sci USA 93:4851–4856 issn: 0027-8424

    PubMed  CAS  Google Scholar 

  • Rosenfeld PJ, Moshfeghi AA, Puliafito CA (2005) Optical co-herence tomography findings after an intravitreal injec-tion of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 36:331–335

    PubMed  Google Scholar 

  • Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY; MARINA Study Group (2006) Ra-nibizumab for neovascular age-related macular degen-eration. N Engl J Med 355:1419–1431

    PubMed  CAS  Google Scholar 

  • Ruzinova MB, Schoer RA, Gerald W, Egan JE, Pandolfi PP, Rafii S, Manova K, Mittal V, Benezra R (2003) Effect of angiogenesis inhibition by Id loss and the contribution of bone-marrow-derived endothelial cells in spontaneous murine tumors. Cancer Cell 4:277–289

    PubMed  CAS  Google Scholar 

  • Ryan AM, Eppler DB, Hagler KE, Bruner RH, Thomford PJ, Hall RL, Shopp GM, O’Neill CA (1999) Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic human-ized monoclonal antibody. Toxicol Pathol 27:78–86

    PubMed  CAS  Google Scholar 

  • Safran M, Kaelin WJ Jr (2003) HIF hydroxylation and the mammalian oxygen-sensing pathway. J Clin Invest 111:779–783

    PubMed  CAS  Google Scholar 

  • Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF (1983) Tumor cells secrete a vascular perme-ability factor that promotes accumulation of ascites fluid. Science 219:983–985

    PubMed  CAS  Google Scholar 

  • Seno H, Oshima M, Ishikawa TO, Oshima H, Takaku K, Chiba T, Narumiya S, Taketo MM (2002) Cyclooxygen-ase 2-and prostaglandin E(2) receptor EP(2)-dependent angiogenesis in Apc(Delta716) mouse intestinal polyps. Cancer Res 62:506–511

    PubMed  CAS  Google Scholar 

  • Shaked Y, Bertolini F, Man S, Rogers MS, Cervi D, Foutz T, Rawn K, Voskas D, Dumont DJ, Ben-David Y, Lawler J, Henkin J, Huber J, Hicklin DJ, D’Amato RJ, Kerbel RS (2005) Genetic heterogeneity of the vasculogenic pheno-type parallels angiogenesis; implications for cellular sur-rogate marker analysis of antiangiogenesis. Cancer Cell 7:101–111

    PubMed  CAS  Google Scholar 

  • Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML, Schuh AC (1995) Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376:62–66

    PubMed  CAS  Google Scholar 

  • Shen H, Clauss M, Ryan J, Schmidt AM, Tijburg P, Borden L, Connolly D, Stern D, Kao J (1993) Characterization of vascular permeability factor/vascular endothelial growth factor receptors on mononuclear phagocytes. Blood 81:2767–2773

    PubMed  CAS  Google Scholar 

  • Shibuya M, Yamaguchi S, Yamane A, Ikeda T, Tojo A, Matsu-shime H, Sato M (1990) Nucleotide sequence and expres-sion of a novel human receptor-type tyrosine kinase (fit) closely related to the fms family. Oncogene 8:519–527

    Google Scholar 

  • Shifren JL, Mesiano S, Taylor RN, Ferrara N, Jaffe RB (1998) Corticotropin regulates vascular endothelial growth fac-tor expression in human fetal adrenal cortical cells. J Clin Endocrinol Metab 83:1342–1347

    PubMed  CAS  Google Scholar 

  • Shweiki D, Itin A, Soffer D, Keshet E (1992) Vascular endo-thelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359:843–845

    PubMed  CAS  Google Scholar 

  • Shweiki D, Itin A, Neufeld G, Gitay-Goren H, Keshet E (1993) Patterns of expression of vascular endothelial growth factor (VEGF) and VEGF receptors in mice suggest a role in hormonally-mediated angiogenesis. J Clin Invest 91:2235–2243

    PubMed  CAS  Google Scholar 

  • Simons M (2005) Angiogenesis: where do we stand now? Cir-culation 111:1556–1566

    Google Scholar 

  • Smith JK, Mamoon NM, Duhe RJ (2004) Emerging roles of targeted small molecule protein-tyrosine kinase inhibi-tors in cancer therapy. Oncol Res 14:175–225

    PubMed  Google Scholar 

  • Soh EY, Sobhi SA, Wong MG, Meng YG, Siperstein AE, Clark OH, Duh QY (1996) Thyroid-stimulating hor-mone promotes the secretion of vascular endothelial growth factor in thyroid cancer cell lines. Surgery 120:944–947

    PubMed  CAS  Google Scholar 

  • Soker S, Fidder H, Neufeld G, Klagsbrun M (1996) Charac-terization of novel vascular endothelial growth factor (VEGF) receptors on tumor cells that bind VEGF 165 via its exon 7-encoded domain. J Biol Chem 271:5761–5767 issn: 0021-9258

    PubMed  CAS  Google Scholar 

  • Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M (1998) Neuropilin-1 is expressed by endothelial and tu-mor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92:735–745

    PubMed  CAS  Google Scholar 

  • Sondell M, Lundborg G, Kanje M (1999) Vascular endothelial growth factor has neurotrophic activity and stimulates axonal outgrowth, enhancing cell survival and Schwann cell proliferation in the peripheral nervous system. J Neu-rosci 19:5731–5740

    CAS  Google Scholar 

  • Sonoshita M, Takaku K, Sasaki N, Sugimoto Y, Ushikubi F, Narumiya S, Oshima M, Taketo MM (2001) Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice. Nat Med 7:1048–1051

    PubMed  CAS  Google Scholar 

  • Sowter HM, Corps AN, Evans AL, Clark DE, Charnock-Jones DS, Smith SK (1997) Expression and localization of the vascular endothelial growth factor family in ovarian epi-thelial tumors. Lab Invest 77:607–614

    PubMed  CAS  Google Scholar 

  • Stacker SA, Achen MG, Jussila L, Baldwin ME, Alitalo K (2002) Lymphangiogenesis and cancer metastasis. Nat Rev Cancer 2:573–583

    PubMed  CAS  Google Scholar 

  • Suzuki K, Hayashi N, Miyamoto Y, Yamamoto M, Ohkawa K, Ito Y, Sasaki Y, Yamaguchi Y, Nakase H, Noda K, Eno-moto N, Arai K, Yamada Y, Yoshihara H, Tujimura T, Kawano K, Yoshikawa K, Kamada T (1996) Expression of vascular permeability factor/vascular endothelial growth factor in human hepatocellular carcinoma. Cancer Res 56:3004–3009

    PubMed  CAS  Google Scholar 

  • Takahashi T, Ueno H, Shibuya M (1999) VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene 18:2221–2230

    PubMed  CAS  Google Scholar 

  • Takahashi T, Yamaguchi S, Chida K, Shibuya M (2001) A single autophosphorylation site on KDR/Flk-1 is essen-tial for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells. Embo J 20:2768–2778

    PubMed  CAS  Google Scholar 

  • Tamagnone L, Artigiani S, Chen H, He Z, Ming GI, Song H, Chedotal A, Winberg ML, Goodman CS, Poo M, Tessier-Lavigne M, Comoglio PM (1999) Plexins are a large family of receptors for transmembrane, secreted, and GPI-an-chored semaphorins in vertebrates. Cell 99:71–80

    PubMed  CAS  Google Scholar 

  • Tejada M, Yu L, Dong J, Jung K, Meng G, Peale FV, Frantz GD, Hall L, Liang X, Gerber HP, Ferrara N (2006) Tu-mor-driven paracrine PDGF receptor-a signaling is a key déterminent of stromal cell recruitment in a model of hu-man lung carcinoma. Clin Cancer Res 12:2676–2688

    PubMed  CAS  Google Scholar 

  • Terman BI, Carrion ME, Kovacs E, Rasmussen BA, Eddy RL, Shows TB (1991) Identification of a new endothelial cell growth factor receptor tyrosine kinase. Oncogene 6:1677–1683 issn: 0950-9232

    PubMed  CAS  Google Scholar 

  • Terman BI, Dougher Vermazen M, Carrion ME, Dimitrov D, Armellino DC, Gospodarowicz D, Bohlen P (1992) Iden-tification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 187:1579–1586 issn: 0006-1291x

    PubMed  CAS  Google Scholar 

  • Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, Abraham JA (1991) The human gene for vas-cular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 266:11947–11954

    PubMed  CAS  Google Scholar 

  • Tomisawa M, Tokunaga T, Oshika Y, Tsuchida T, Fukushima Y, Sato H, Kijima H, Yamazaki H, Ueyama Y, Tamaoki N, Nakamura M (1999) Expression pattern of vascular en-dothelial growth factor isoform is closely correlated with tumour stage and vascularisation in renal cell carcinoma. Eur J Cancer 35:133–137

    PubMed  CAS  Google Scholar 

  • Tran J, Master Z, Yu JL, Rak J, Dumont DJ, Kerbel RS (2002) A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci USA 99:4349–4354

    PubMed  CAS  Google Scholar 

  • Tsuzuki Y, Fukumura D, Oosthuyse B, Koike C, Carmeliet P, Jain RK (2000) Vascular endothelial growth factor (VEGF) modulation by targeting hypoxia-inducible fac-tor-1alpha-hypoxia response element-VEGF cascade differentially regulates vascular response and growth rate in tumors. Cancer Res 60:6248–6252

    PubMed  CAS  Google Scholar 

  • Uchida S, Shimada Y, Watanabe G, Tanaka H, Shibagaki I, Miyahara T, Ishigami S, Imamura M (1998) In oesoph-ageal squamous cell carcinoma vascular endothelial growth factor is associated with p53 mutation, advanced stage and poor prognosis. Br J Cancer 77:1704–1709

    PubMed  CAS  Google Scholar 

  • Vaisman N, Gospodarowicz D, Neufeld G (1990) Character-ization of the receptors for vascular endothelial growth factor. J Biol Chem 265:19461–19466

    PubMed  CAS  Google Scholar 

  • Vincenti V, Cassano C, Rocchi M, Persico G (1996) Assign-ment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation 93:1493–1495 issn: 0009-7322

    PubMed  CAS  Google Scholar 

  • Volm M, Koomagi R, Mattern J (1997) Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer. Int J Cancer 74:64–68

    PubMed  CAS  Google Scholar 

  • Waltenberger J, ClaessonWelsh L, Siegbahn A, Shibuya M, Heldin CH (1994) Different signal transduction proper-ties of KDR and Flt1, two receptors for vascular endo-thelial growth factor. J Biol Chem 269:26988–26995 issn: 20021-29258

    PubMed  CAS  Google Scholar 

  • Wang GL, Semenza GL (1995) Purification and characteriza-tion of hypoxia-inducible factor 1. J Biol Chem 270:1230–1237 issn: 0021-9258

    PubMed  CAS  Google Scholar 

  • Warren RS, Yuan H, Matli MR, Gillett NA, Ferrara N (1995) Regulation by vascular endothelial growth factor of hu-man colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 95:1789–1797 issn: 0021-9738

    PubMed  CAS  Google Scholar 

  • Warren RS, Yuan H, Matli MR, Ferrara N, Donner DB (1996) Induction of vascular endothelial growth factor by insu-lin-like growth factor 1 in colorectal carcinoma. J Biol Chem 271:29483–29488

    PubMed  CAS  Google Scholar 

  • Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Curwen JO, Hen-nequin LF, Thomas AP, Stokes ES, Curry B, Richmond GH, Wadsworth PF (2000)ZD4190: an orally active in-hibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy. Cancer Res 60:970–975

    PubMed  CAS  Google Scholar 

  • Willett CG, Boucher Y, Di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK (2004) Direct evi-dence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10:145–147

    PubMed  CAS  Google Scholar 

  • Williams CS, Tsujii M, Reese J, Dey SK, DuBois RN (2000) Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 105:1589–1594

    PubMed  CAS  Google Scholar 

  • Wise LM, Veikkola T, Mercer AA, Savory LJ, Fleming SB, Caesar C, Vitali A, Makinen T, Alitalo K, Stacker SA (1999) Vascular endothelial growth factor (VEGF)-like protein from orf virus NZ2 binds to VEGFR2 and neuro-pilin-1. Proc Natl Acad Sci USA 96:3071–3076

    PubMed  CAS  Google Scholar 

  • WizigmannVoos S, Breier G, Risau W, Plate KH (1995) Up-regulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastomas. Cancer Res 55:1358–1364 issn: 0008-5472

    CAS  Google Scholar 

  • Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, Hofmann F, Mestan J, Mett H, O’Reilly T, Persohn E, Rosel J, Schnell C, Stover D, Theuer A, Towbin H, Wenger F, Woods-Cook K, Menrad A, Siemeister G, Schirner M, Thierauch KH, Schneider MR, Drevs J, Martiny-Baron G, Totzke F (2000) PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 60:2178–2189

    PubMed  CAS  Google Scholar 

  • Wu LW, Mayo LD, Dunbar JD, Kessler KM, Baerwald MR, Jaffe EA, Wang D, Warren RS, Donner DB (2000) Utiliza-tion of distinct signaling pathways by receptors for vas-cular endothelial cell growth factor and other mitogens in the induction of endothelial cell proliferation. J Biol Chem 275:5096–5103

    PubMed  CAS  Google Scholar 

  • Yamamoto S, Konishi I, Mandai M, Kuroda H, Komatsu T, Nanbu K, Sakahara H, Mori T (1997) Expression of vascu-lar endothelial growth factor (VEGF) in epithelial ovar-ian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. Br J Cancer 76:1221–1227

    PubMed  CAS  Google Scholar 

  • Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J (2000) Vascular-specific growth factors and blood vessel formation. Nature 407:242–248

    PubMed  CAS  Google Scholar 

  • Yoshiji H, Gomez DE, Shibuya M, Thorgeirsson UP (1996) Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. Cancer Res 56:2013–2016 issssn: 0008-5472

    PubMed  CAS  Google Scholar 

  • Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK (1996) Time-dependent vascular regression and perme-ability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/ vascular permeability factor antibody. Proc Natl Acad Sci USA 93:14765–14770

    PubMed  CAS  Google Scholar 

  • Yuan L, Moyon D, Pardanaud L, Breant C, Karkkainen MJ, Alitalo K, Eichmann A (2002) Abnormal lymphatic vessel development in neuropilin 2 mutant mice. Development 129:4797–4806

    PubMed  CAS  Google Scholar 

  • Zhang X, Gaspard JP, Chung DC (2001) Regulation of vascu-lar endothelial growth factor by the Wnt and K-ras path-ways in colonic neoplasia. Cancer Res 61:6050–6054

    PubMed  CAS  Google Scholar 

  • Zimmermann RC, Hartman T, Bohlen P, Sauer MV, Kitajew-ski J, (2001a) Preovulatory treatment of mice with anti-VEGF receptor 2 antibody inhibits angiogenesis in cor-pora lutea. Microvasc Res 62:15–25

    PubMed  CAS  Google Scholar 

  • Zimmermann RC, Xiao E, Husami N, Sauer MV, Lobo R, Kitajewski J, Ferin M (2001b) Short-term administra-tion of antivascular endothelial growth factor antibody in the late follicular phase delays follicular develop-ment in the rhesus monkey. J Clin Endocrinol Metab 86:768–772

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Molecular Oncology, Genentech, Inc., 1 DNA Way, South San Francisco, CA, 94080, USA

    Dr. Napoleone Ferrara

Authors
  1. Dr. Napoleone Ferrara
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik für Tumorbiologie, Breisacher Str. 117, 79106, Freiburg i. Br., Germany

    Dieter Marmé PhD (Professor) (Professor)

  2. DKFZ, Im Neuenheimer Feld 280, 69120, Heidelberg, Germany

    Norbert Fusenig MD (Professor, former Head of Division of Carcinogenesis and Differentiation) (Professor, former Head of Division of Carcinogenesis and Differentiation)

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Ferrara, N. (2008). Pathophysiology and Clinical Implications of Vascular Endothelial Growth Factor. In: Marmé, D., Fusenig, N. (eds) Tumor Angiogenesis. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-33177-3_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-33177-3_5

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-33176-6

  • Online ISBN: 978-3-540-33177-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation